ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
PCDH1 Facilitates Migration, Proliferation, and Stemness of Pancreatic Cancer Cells through PI3K-Akt and IGF-1 Signaling
Provisionally accepted
- 1First Affiliated Hospital of Harbin Medical University, Harbin, China
- 2The Fifth Affiliated Hospital of Zunyi Medical University Zhuhai, Zhuhai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Pancreatic ductal adenocarcinoma (PDAC) exhibits high lethality due to late diagnosis, therapy resistance, and cancer stem cell (CSC)-driven progression. However, the molecular determinants of stemness in PDAC remain unclear. Methods: We integrated RNA-sequencing and clinical data from TCGA to calculate stemness indices and identify hub genes using weighted co-expression network analysis and differential expression profiling. PCDH1 expression was validated in PDAC tissues by qRT-PCR and immunohistochemistry. Functional assays, including MTT, colony formation, Transwell, wound healing, flow cytometry, and spheroid culture, were performed following PCDH1 knockdown. Transcriptome sequencing was used to delineate downstream signaling mechanisms. Results: PCDH1 emerged as a stemness-associated oncogene strongly linked to poor survival. It was markedly overexpressed in PDAC tissues and cell lines. Silencing PCDH1 significantly impaired proliferation, clonogenicity, migration, and CSC frequency. Sphere-forming ability was also reduced. Transcriptomic analysis revealed downregulation of PI3K/AKT signaling upon PCDH1 knockdown, and rescue experiments confirmed its role in driving PDAC progression through PI3K/AKT activation. High PCDH1 expression further correlated with immune exclusion and distinctive patterns of chemosensitivity. Conclusion: PCDH1 is a novel stemness-linked oncogene that accelerates PDAC progression via PI3K/AKT signaling. Its prognostic relevance, association with immune evasion, and impact on drug responsiveness highlight PCDH1 as a promising biomarker and therapeutic target for CSC-directed intervention in PDAC.
Keywords: gene, Pancreatic Ductal Adenocarcinoma, Pcdh1, Stemness index, verification
Received: 01 Sep 2025; Accepted: 12 Dec 2025.
Copyright: © 2025 Yang, Zhipeng, Song, Dai, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Weihui Zhang
Dali Zhao
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.